Clinical Trials · NCT05371028

A Study of Teduglutide (Revestive®) in Participants With Short Bowel Syndrome (SBS) in Canada

Name: A Study of Teduglutide (Revestive®) in Participants With Short Bowel Syndrome (SBS) in Canada
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedN/ATeduglutide

Phase: N/A
Recruitment status: Completed
Sponsor: Takeda
Enrollment: 52
Start date: Sep 2023
Locations: 1 site, Canada
Primary endpoint: Change From Baseline in Weekly Volume of Parenteral Nutrition (PN)/Intravenous (IV) Fluid Requirement at Week 24

View Teduglutide compound reference